CLINICAL TRIALS PROFILE FOR TENOFOVIR ALAFENAMIDE FUMARATE
✉ Email this page to a colleague
All Clinical Trials for Tenofovir Alafenamide Fumarate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00036634 ↗ | A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients | Completed | Gilead Sciences | Phase 1/Phase 2 | 2002-03-01 | This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate (tenofovir DF). |
| NCT01497899 ↗ | Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | Completed | Gilead Sciences | Phase 2 | 2011-12-28 | The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®; E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®; E/C/F/TDF) FDC in HIV-1 infected, antiretroviral treatment-naive adults. |
| NCT01565850 ↗ | D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults | Completed | Gilead Sciences | Phase 2 | 2012-04-01 | This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in HIV-1 infected, antiretroviral treatment-naive adults as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24. |
| NCT01780506 ↗ | Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults | Completed | Gilead Sciences | Phase 3 | 2012-12-26 | The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults. |
| NCT01797445 ↗ | Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults | Completed | Gilead Sciences | Phase 3 | 2013-03-12 | The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) in HIV-1 positive, antiretroviral treatment-naive adults. |
| NCT01815736 ↗ | Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants | Completed | Gilead Sciences | Phase 3 | 2013-03-27 | The primary objective of this study is to evaluate the non-inferiority of switching to a tenofovir alafenamide (TAF)-containing fixed dose combination (FDC) relative to maintaining tenofovir disoproxil fumarate (TDF)-containing combination regimens in virologically suppressed HIV-infected participants as determined by having HIV-1 RNA < 50 copies/mL at Week 48. |
| NCT01940341 ↗ | Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B | Active, not recruiting | Gilead Sciences | Phase 3 | 2013-09-01 | The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B virus (HBV) infection. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Tenofovir Alafenamide Fumarate
Condition Name
Clinical Trial Locations for Tenofovir Alafenamide Fumarate
Trials by Country
Clinical Trial Progress for Tenofovir Alafenamide Fumarate
Clinical Trial Phase
Clinical Trial Sponsors for Tenofovir Alafenamide Fumarate
Sponsor Name
| Sponsor Name for Tenofovir Alafenamide Fumarate | |
| Sponsor | Trials |
| Gilead Sciences | 35 |
| Third Affiliated Hospital, Sun Yat-Sen University | 5 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 4 |
| [disabled in preview] | 8 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
